Scholar Rock Holding Current Ratio 2017-2021 | SRRK

Scholar Rock Holding current ratio from 2017 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Scholar Rock Holding Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.29B $0.07B 4.33
2021-03-31 $0.32B $0.07B 4.55
2020-12-31 $0.34B $0.04B 8.09
2020-09-30 $0.12B $0.03B 3.63
2020-06-30 $0.15B $0.03B 4.46
2020-03-31 $0.16B $0.03B 6.06
2019-12-31 $0.19B $0.03B 5.64
2019-09-30 $0.18B $0.03B 5.51
2019-06-30 $0.19B $0.03B 5.88
2019-03-31 $0.16B $0.03B 4.76
2018-12-31 $0.18B $0.03B 5.72
2018-09-30 $0.11B $0.01B 18.43
2018-06-30 $0.12B $0.01B 17.49
2018-03-31 $0.00B 0.00
2017-12-31 $0.00B 0.00
2017-09-30 $0.00B 0.00
2017-06-30 $0.00B 0.00
2016-12-31 $0.03B $0.00B 9.48
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.903B $0.015B
Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76